• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝内胆管癌的分期。

Staging of intrahepatic cholangiocarcinoma.

机构信息

Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

出版信息

Curr Opin Gastroenterol. 2010 May;26(3):269-73. doi: 10.1097/MOG.0b013e328337c899.

DOI:10.1097/MOG.0b013e328337c899
PMID:20179593
Abstract

PURPOSE OF REVIEW

Staging of intrahepatic cholangiocarcinoma (ICC) has historically mirrored that for hepatocellular carcinoma, largely due to the fact that ICC has been an uncommon disease. This review summarizes recent developments related to prognostication in ICC that have allowed the development of a distinct Western staging system for this disease.

RECENT FINDINGS

A large cancer registry study focused on identification of prognostic factors after resection of ICC with the aim of developing a distinct staging system for ICC. On the basis of this analysis and corroborative data from smaller institutional series, the American Joint Committee on Cancer (AJCC) 7th edition staging manual includes a distinct staging system for ICC that focuses on multiple tumors, vascular invasion, and lymph node metastasis. This system is simpler than the AJCC 6th edition staging yet preserves prognostic discrimination; the new system is also significantly superior to the Japanese staging system. Some evidence suggests that the number of lymph nodes involved by tumor may influence prognosis. Margin-negative resection is a major therapeutic determinant of outcome in ICC and should be pursued unless distant metastasis is present.

SUMMARY

For the first time, a distinct staging system for ICC has been adopted by the AJCC. Understanding of prognostic factors in ICC remains incomplete but is improving. This field is in evolution, and further refinements to the staging of ICC are likely as more data emerge on this increasingly common malignancy.

摘要

目的综述

肝内胆管癌(ICC)的分期在很大程度上与肝细胞癌(HCC)的分期相似,主要是因为 ICC 是一种罕见的疾病。这篇综述总结了与 ICC 预后相关的最新进展,这些进展使得为这种疾病制定了一个独特的西方分期系统。

最近的发现

一项针对 ICC 切除术后预后因素的大型癌症登记研究旨在为 ICC 制定一个独特的分期系统。基于这项分析以及来自较小机构系列的佐证数据,美国癌症联合委员会(AJCC)第 7 版分期手册包括了一个针对 ICC 的独特分期系统,该系统侧重于多个肿瘤、血管侵犯和淋巴结转移。与 AJCC 第 6 版分期相比,该系统更简单,但保留了预后区分度;新系统也明显优于日本分期系统。有一些证据表明,肿瘤累及的淋巴结数量可能影响预后。ICC 中阴性切缘的切除是治疗结果的主要决定因素,除非存在远处转移,否则应进行该手术。

总结

AJCC 首次为 ICC 采用了独特的分期系统。对 ICC 预后因素的理解仍不完整,但正在不断完善。随着更多关于这种日益常见的恶性肿瘤的数据出现,ICC 的分期可能会进一步细化。

相似文献

1
Staging of intrahepatic cholangiocarcinoma.肝内胆管癌的分期。
Curr Opin Gastroenterol. 2010 May;26(3):269-73. doi: 10.1097/MOG.0b013e328337c899.
2
Evaluation of the 8th edition American Joint Commission on Cancer (AJCC) staging system for patients with intrahepatic cholangiocarcinoma: A surveillance, epidemiology, and end results (SEER) analysis.美国癌症联合委员会(AJCC)第8版肝内胆管癌患者分期系统评估:一项监测、流行病学及最终结果(SEER)分析
J Surg Oncol. 2017 Nov;116(6):643-650. doi: 10.1002/jso.24720. Epub 2017 Jun 12.
3
Prognostic comparison of the 7th and 8th editions of the American Joint Committee on Cancer staging system for intrahepatic cholangiocarcinoma.第七版和第八版美国癌症联合委员会分期系统对肝内胆管癌预后的比较。
J Hepatobiliary Pancreat Sci. 2018 Apr;25(4):240-248. doi: 10.1002/jhbp.543.
4
Proposal of a new staging system for mass-forming intrahepatic cholangiocarcinoma: a multicenter analysis by the Study Group for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery.肝内胆管癌肿块形成新分期系统的提议:日本肝胆胰外科学会肝脏外科学研究组的多中心分析
J Hepatobiliary Pancreat Sci. 2014 Jul;21(7):499-508. doi: 10.1002/jhbp.92. Epub 2014 Feb 12.
5
Surgical Management of Intrahepatic Cholangiocarcinoma: Defining an Optimal Prognostic Lymph Node Stratification Schema.肝内胆管癌的外科治疗:定义一种最佳的预后性淋巴结分层方案。
Ann Surg Oncol. 2015 Aug;22(8):2772-8. doi: 10.1245/s10434-015-4419-1. Epub 2015 Feb 7.
6
Modified staging classification for intrahepatic cholangiocarcinoma based on the sixth and seventh editions of the AJCC/UICC TNM staging systems.基于美国癌症联合委员会(AJCC)/国际抗癌联盟(UICC)TNM分期系统第六版和第七版的肝内胆管癌改良分期分类
Medicine (Baltimore). 2017 Aug;96(34):e7891. doi: 10.1097/MD.0000000000007891.
7
A proposed staging system for intrahepatic cholangiocarcinoma.一种针对肝内胆管癌的拟议分期系统。
Ann Surg Oncol. 2009 Jan;16(1):14-22. doi: 10.1245/s10434-008-0180-z. Epub 2008 Nov 6.
8
Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment.肝内胆管细胞癌:国际多机构分析预后因素和淋巴结评估。
J Clin Oncol. 2011 Aug 10;29(23):3140-5. doi: 10.1200/JCO.2011.35.6519. Epub 2011 Jul 5.
9
Serosal invasion in TNM staging of mass-forming intrahepatic cholangiocarcinoma.肿块型肝内胆管癌TNM分期中的浆膜侵犯
J Hepatobiliary Pancreat Surg. 2005;12(6):479-83. doi: 10.1007/s00534-005-1026-8.
10
Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.肝细胞癌合并胆管细胞癌:临床特征、治疗方式和预后。
Ann Surg Oncol. 2012 Sep;19(9):2869-76. doi: 10.1245/s10434-012-2328-0. Epub 2012 Mar 27.

引用本文的文献

1
Standardized reporting of intrahepatic cholangiocarcinoma.肝内胆管癌的标准化报告
Abdom Radiol (NY). 2025 Apr;50(4):1584-1594. doi: 10.1007/s00261-024-04582-4. Epub 2024 Oct 7.
2
Lymph Node Dissection in Intrahepatic Cholangiocarcinoma: a Critical and Updated Review of the Literature.肝内胆管癌淋巴结清扫:文献综述的关键和最新回顾。
J Gastrointest Surg. 2023 Dec;27(12):3001-3013. doi: 10.1007/s11605-023-05696-8. Epub 2023 Aug 7.
3
Clinical Features and Prognostic Models in Patients with Intrahepatic Cholangiocarcinoma: a Population-Based Analysis.
肝内胆管癌患者的临床特征及预后模型:一项基于人群的分析
J Gastrointest Surg. 2023 May;27(5):945-955. doi: 10.1007/s11605-023-05602-2. Epub 2023 Feb 2.
4
A2M is a potential core gene in intrahepatic cholangiocarcinoma.A2M 是肝内胆管癌的一个潜在核心基因。
BMC Cancer. 2022 Jan 3;22(1):5. doi: 10.1186/s12885-021-09070-2.
5
Strengths and Limitations of Registries in Surgical Oncology Research.外科肿瘤学研究中注册研究的优势和局限性。
J Gastrointest Surg. 2021 Nov;25(11):2989-2996. doi: 10.1007/s11605-021-05094-y. Epub 2021 Sep 10.
6
Intrahepatic Cholangiocarcinoma.肝内胆管癌
Semin Intervent Radiol. 2020 Dec;37(5):475-483. doi: 10.1055/s-0040-1719188. Epub 2020 Dec 11.
7
Intrahepatic cholangiocarcinoma: pathogenesis, current staging, and radiological findings.肝内胆管细胞癌:发病机制、当前分期和影像学表现。
Abdom Radiol (NY). 2020 Nov;45(11):3662-3680. doi: 10.1007/s00261-020-02559-7.
8
The role of down staging treatment in the management of locally advanced intrahepatic cholangiocarcinoma: Review of literature and pooled analysis.降期治疗在局部晚期肝内胆管癌管理中的作用:文献综述与汇总分析
Ann Hepatobiliary Pancreat Surg. 2020 Feb;24(1):6-16. doi: 10.14701/ahbps.2020.24.1.6. Epub 2020 Feb 27.
9
Prognostic Factors and Treatment Strategies for Intrahepatic Cholangiocarcinoma from 2004 to 2013: Population-Based SEER Analysis.2004年至2013年肝内胆管癌的预后因素及治疗策略:基于人群的监测、流行病学和结果(SEER)分析
Transl Oncol. 2019 Nov;12(11):1496-1503. doi: 10.1016/j.tranon.2019.05.020. Epub 2019 Aug 22.
10
DLEC1 methylation is associated with a better clinical outcome in patients with intrahepatic cholangiocarcinoma of the small duct subtype.DLEC1 甲基化与小胆管型肝内胆管细胞癌患者的更好临床结局相关。
Virchows Arch. 2019 Jul;475(1):49-58. doi: 10.1007/s00428-018-02511-7. Epub 2019 Jan 4.